ATLANTA--(BUSINESS WIRE)--MIV Therapeutics Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has cited a number of recent publications that sharply define the critical need for new technology the Company is developing to prevent the most common and serious type of stroke associated with heart surgery and other procedures.
